oktober 10, 2019
SAN DIEGO and COPENHAGEN, Denmark, Oct. 9, 2019 /PRNewswire/ — AFYX Therapeutics, a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced results from a Phase 1 clinical proof of concept study evaluating the use of the Rivelin® bio-adhesive patch in patients with vulvar lichen sclerosus (VLS), a painful genital skin condition that affects up to 3% of post-menopausal women....


Vil undersøge evt. sammenhæng mellem hovedpinepiller og tidlige ufrivillige aborter
6. januar 2020
Kræftpatienter donerer levende hjerneceller til forskere
17. december 2019
Lundbeckfonden giver 60 mio. kr. til dristige videnskabelige ideer
11. december 2019


Lundbeckfonden Ventures

Lundbeckfonden Emerge